Recruiting

NCT Number: NCT07312474

Epidemiological, Clinical and Biological Characteristics of Human Anaplasmosis Cases in Alsace

Anaplasmosis is a bacterial infection caused by the intracellular bacterium Anaplasma phagocytophilum and transmitted by ticks. This bacterium is present in approximately 1% of ticks in Alsace. This infection is responsible for clinical manifestations that are most often mild, including fever, headache, and myalgia, occurring 2 to 3 weeks after a tick bite. However, this infection can be accompanied by potentially serious or even fatal complications, including severe cytopenias, acute respiratory distress syndrome, septic shock, severe neurological disorders, hemorrhagic manifestations, macrophage activation syndrome, and multiple organ failure. Mortality is variable and appears to be higher in American studies, where it is around 4%. Treatment is well-established and relies on doxycycline, which is highly effective. Although a few cases have been described in France, these are mostly isolated cases or short series of cases, whereas Belgium, Poland, and Slovenia have reported numerous cases. Thus, there is a lack of data on French cases, and given that Alsace is in a region with a high prevalence of tick-borne diseases, data is needed to better understand the epidemiology and to better identify suspected cases in order to provide appropriate care.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Human Anaplasmosis Anaplasmataceae Infections Anaplasmosis Animal Diseases Bacterial Infections Bacterial Infections and Mycoses Bites and Stings Chemically-Induced Disorders Cytopenia Gram-Negative Bacterial Infections Hematologic Diseases Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Infections Inflammation Lung Diseases Lymphoproliferative Disorders Macrophage Activation Syndrome Nervous System Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Poisoning Respiration Disorders Respiratory Distress Syndrome Respiratory Tract Diseases Sepsis Shock Shock, Septic Systemic Inflammatory Response Syndrome Tick Bites Tick-Borne Diseases Vector Borne Diseases Wounds and Injuries

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France

Strasbourg, 67091, France

Location status: Recruiting

Location contact

Baptiste Hoellinger, MD

SUB_INVESTIGATOR

Pierre Boyer, PharmD

SUB_INVESTIGATOR

Thomas Bonijoly, MD

PRINCIPAL_INVESTIGATOR

Thomas Lemmet, MD

PRINCIPAL_INVESTIGATOR

Victor Gerber, MD

CONTACT

[email protected]

33 3.88.11.67.68

Victor Gerber, MD

PRINCIPAL_INVESTIGATOR

Yves Hansmann, MD

SUB_INVESTIGATOR

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adult subjct (≥18 years)
Presenting with a PCR-confirmed infection of Anaplasma

Exclusion criteria

Refusal to participate in the study

Treatment and study plan

Primary outcomes

Mortality of cases of human anaplasmosis in Alsace

Time frame: Up to 12 years

Study contacts

Contact information is provided by the study sponsor or research team.

Victor GERBER, MD

CONTACT

[email protected]

33 3.88.11.67.68

Sponsors and collaborators

Lead sponsor

University Hospital, Strasbourg, France

Other

Registry information

Official study title

Epidemiological, Clinical and Biological Characteristics of Human Anaplasmosis Cases in Alsace: a Retrospective and Multicenter Study

Acronym: ANARETRO

Important dates

Study start: 2024
Primary completion: 2026
Study completion: 2026
First posted: Dec 31, 2025
Registry last updated: Dec 31, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting